Adarza BioSystems is an early stage medical diagnostics company developing a rapid and label-free biological assay platform for measuring clinical and point-of-care (POC) samples. In addition to performing sophisticated clinical tests within minutes, this technology is fully arrayable, potentially allowing hundreds of tests to be run simultaneously on a single chip.
Funding Rounds (5) - $14.05MUpdate
Current Team (5)Update
|Mar 21, 2016||PE HUB - Adarza BioSystems closes $5 mln Series B|
|Mar 21, 2016||Boston Tech Flash - St. Louis startup raises $5 million from group led by Cultivation Capital, Lewis & Clark Ventures|
|Mar 21, 2016||Democrat and Chronical - URMC startup lands $5M in funding|
|Jun 2, 2015||PRNewswire UK All - Global Molecular Diagnostics Report 2015-2019 - Market Size, Strategy and Forecasts|
|Jun 2, 2015||Business Wire - Research and Markets: Molecular Diagnostics - Global Market Size, Strategy and Forecasts - 2015 to 2019|
|May 5, 2015||PRNewswire UK All - European Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2015-2019|
|May 5, 2015||PRNewswire UK All - Asia Pacific Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Report 2015-2019|
|Oct 2, 2014||Boston Tech Flash - Cultivation Capital, Siemens help Adarza raise $6.8 million - St. Louis Business Journal|
150 Lucius Gordon Dr., Suite 100
West Henrietta, NY 14586
4041 Forest Park Ave.
St Louis, MO 63108